View Full Paper

Owner Consent Verified
Essay 4.3

Clinical Trials Adoption in Fortune 500 Firms: Resilience And Continuity — A Comparative Perspective

9
Pages
Chicago
Style
~ 9–15 mins
Reading Time
BioMed MLOps Public Policy
Abstract

This essay investigates “Clinical Trials Adoption in Fortune 500 Firms: Resilience And Continuity — A Comparative Perspective” using a Delphi study. Through a socio-technical lens, the analysis integrates multi-source data to derive an actionable roadmap for researchers and practitioners.

Download PDF Order Similar Paper Save

Clinical Trials Adoption in Fortune 500 Firms: Resilience And Continuity — A Comparative Perspective

ABSTRACT
Clinical Trials Adoption in Fortune 500 Firms: Resilience And Continuity — A Comparative Perspective is unpacked across themes: interoperability, equity, ethics, and KPIs. Limitations and future research paths are noted.
1
Open full preview
Related Papers
Browse all
21 Pages 4.4
Quantum Computing for Data Science Teams: Change Management | Evidence from Nordic Countries
Data Privacy Supply Chain HCI
View Paper
25 Pages 4.8
Impact Investing and Resilience And Continuity among NGOs in Global Health — 2024–2028 Trends
Blockchain Risk Marketing
View Paper
9 Pages 4.9
Logistics Optimization and Sustainability Outcomes among EU Startups — Post-Pandemic Lessons
Tourism FinTech DevSecOps
View Paper